Charles L. Sawyers, MD, discusses the value of atezolizumab, cobimetinib, and vemurafenib in the melanoma treatment landscape.
Charles L. Sawyers, MD, internist and hematologic oncologist; chair of the Human Oncology and Pathogenesis Program; and Marie-Josée and Henry R. Kravis Chair at Memorial Sloan Kettering Cancer Center, discusses the value of atezolizumab (Tecentriq), cobimetinib (Cotellic), and vemurafenib (Zelboraf) in the melanoma treatment landscape.
The phase 3 IMspire150 trial (NCT02908672) investigated this triplet regimen in patients with previously untreated patients with metastatic or unresectable locally advanced melanoma and a BRAFV600 mutation. The trial showed efficacy of this triplet regimen by meeting its primary end point of progression-free survival (PFS). Sawyers says that although it is great that it worked for these patients, the field has moved forward at a rapid pace.
Although the comparison in this trial was compelling at the time it was designed, it’s now troubling because the standard of care for these patients is ipilimumab (Yervoy) and PD-1/PD-L1 antibodies, which has shown impressive efficacy in early trials and in a 5-year follow-up, according to Sawyers. About 40% of patients have PFS at 5 years, which may be hard to surpass with the IMspire150 trial. Comparisons of these 2 types of regimens are moving forward in this setting.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More